The purpose of this study is to understand the epidemiology and pathophysiology of Paxlovid rebound in patients with acute Covid-19 infection who have been prescribed the Paxlovid per standard of care.~The study will be a collaborative effort between Scripps and eMed, digitally recruiting 800 participants who have tested positive for Covid-19 and have agreed to be prescribed Paxlovid on the eMed platform.~The vision of the study is to understand Paxlovid rebound and ultimately inform management of acute Covid-19 infection.
A prospective monitoring study for those individuals treated with Paxlovid